BLOOD

Scope & Guideline

Transforming Insights into Blood Science.

Introduction

Welcome to your portal for understanding BLOOD, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0006-4971
PublisherAMER SOC HEMATOLOGY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1946 to 2024
AbbreviationBLOOD / Blood
Frequency52 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2021 L ST NW, SUITE 900, WASHINGTON, DC 20036

Aims and Scopes

The journal 'BLOOD' focuses on advancing the field of hematology through innovative research that encompasses various aspects of blood disorders, including their biology, diagnosis, treatment, and patient management.
  1. Hematologic Malignancies:
    A core focus of the journal is on hematologic cancers such as leukemia, lymphoma, and myeloma, including studies on their molecular mechanisms, therapeutic strategies, and clinical outcomes.
  2. Transfusion Medicine and Hemostasis:
    Research related to blood transfusion practices, coagulation disorders, and the management of bleeding disorders is prominently featured, emphasizing both clinical and laboratory aspects.
  3. Genomics and Precision Medicine:
    The journal publishes studies on the genetic basis of blood disorders and the application of genomic technologies to personalize treatment approaches.
  4. Immunotherapy and Novel Therapeutics:
    There is a significant focus on immunotherapeutic strategies, including CAR T-cell therapies and monoclonal antibodies, aimed at treating various hematologic malignancies.
  5. Patient-Centered Care and Quality of Life:
    Research addressing the psychosocial aspects of hematologic diseases, including patient-reported outcomes and the impact of treatment on quality of life, is increasingly emphasized.
  6. Clinical Trials and Real-World Evidence:
    The journal highlights findings from clinical trials as well as real-world studies that provide insights into treatment effectiveness and safety in diverse populations.
The journal 'BLOOD' has witnessed a notable evolution in its scope, with emerging themes reflecting the latest advancements in hematologic research and clinical practice. These trends highlight the journal's commitment to addressing contemporary challenges in hematology.
  1. CAR T-Cell Therapy:
    There is a significant increase in research related to CAR T-cell therapies, including their development, efficacy, and management of associated toxicities, reflecting the growing importance of this treatment modality in hematologic malignancies.
  2. Genetic and Molecular Profiling:
    Studies focusing on genetic mutations, epigenetic changes, and their implications for disease progression and treatment response are becoming increasingly prevalent, emphasizing the role of precision medicine in hematology.
  3. Real-World Evidence and Health Economics:
    The journal is increasingly publishing articles that analyze real-world data to evaluate treatment outcomes and healthcare costs, highlighting the importance of pragmatic approaches in clinical decision-making.
  4. Immunotherapy Combinations:
    Emerging research on combining immunotherapies with other treatment modalities, such as targeted therapies and traditional chemotherapy, is gaining momentum, indicating a shift towards multi-faceted treatment strategies.
  5. Patient-Centered Research:
    An emphasis on patient-reported outcomes, quality of life assessments, and studies addressing the psychosocial aspects of hematologic diseases is becoming more pronounced, reflecting a holistic approach to patient care.

Declining or Waning

While the journal 'BLOOD' continues to explore a wide array of topics within hematology, certain areas have seen a decrease in focus or publication frequency over the years, reflecting evolving research priorities and advancements in the field.
  1. Traditional Chemotherapy Approaches:
    There is a declining emphasis on classical chemotherapy regimens for hematologic malignancies as newer targeted therapies and immunotherapies gain prominence.
  2. Basic Hematology Research:
    Research focused solely on basic hematology without immediate clinical application appears to be waning, as the journal increasingly prioritizes translational and clinical studies.
  3. Epidemiological Studies:
    While still relevant, the volume of purely epidemiological studies on blood disorders has decreased, with a shift towards more integrated approaches that combine clinical outcomes with genomic and molecular data.
  4. Single-Agent Therapy Studies:
    The focus on studies evaluating the efficacy of single-agent therapies has diminished, as combination therapies are recognized for their enhanced effectiveness in treating complex hematologic conditions.
  5. Niche Hematologic Disorders:
    Research on less common hematologic conditions may be receiving less attention in favor of more prevalent disorders and broader therapeutic strategies.

Similar Journals

Indian Journal of Hematology and Blood Transfusion

Pioneering Research in Hematology for Tomorrow's Healthcare
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

EUROPEAN JOURNAL OF HAEMATOLOGY

Connecting Experts in the Evolving Field of Hematology
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

BLOOD REVIEWS

Fostering innovation in the science of blood.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

ANNALS OF HEMATOLOGY

Pioneering insights in the ever-evolving field of hematology.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Advancing the Science of Blood Health
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Hemato

Transforming Discoveries into Global Health Solutions
Publisher: MDPIISSN: Frequency: 4 issues/year

Hemato is a pioneering open-access journal dedicated to the field of hematology, published by the esteemed MDPI from its base in Basel, Switzerland. Launched in 2020, this journal aims to provide a platform for researchers, clinicians, and professionals to share significant findings and advancements in blood-related disciplines over a converged timeframe until 2024. With a commitment to disseminating high-quality research, Hemato seeks to foster collaboration and innovation in hematological studies, showcasing original articles, reviews, and clinical studies that contribute to expanding knowledge in this vital area. As an open-access journal, it promotes accessible scholarship, ensuring that groundbreaking research reaches a broad audience, thereby enhancing the impact on the global health community.

Blood Cancer Discovery

Exploring Innovations in Oncology and Beyond
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi

Fostering global collaboration in blood disorder research.
Publisher: AKAD DOKTORLAR YAYINEVIISSN: 1306-133XFrequency: 4 issues/year

UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi, published by AKAD DOKTORLAR YAYINEVI, is a pivotal journal in the fields of hematology and oncology, catering to an international audience of researchers, clinicians, and students. Since its inception in 2005, the journal has committed to disseminating high-quality, peer-reviewed research, highlighting advancements and challenges in the diagnosis and treatment of hematological and oncological disorders. Registered under ISSN 1306-133X, it serves as a significant platform for scholarly discourse, despite its recent categorization in the Q4 quartile for both hematology and oncology—indicating opportunities for growth and contribution within the scientific community. While currently not Open Access, the journal's indexed contribution to Scopus ranks it within the 12th and 17th percentiles in the domains of hematology and oncology respectively, reflecting its emerging presence within the academic landscape. As it approaches its convergence point in 2024, UHOD strives to elevate its influence, providing invaluable insights and fostering collaborations in the ongoing fight against blood disorders and cancer.

Turkish Journal of Hematology

Pioneering insights into blood disorders and treatments.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Egyptian Journal of Haematology

Exploring Breakthroughs in Blood Health and Disease
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.